Not your mom’s pro­bi­ot­ic: GV-backed Evelo teams up with Mayo Clin­ic on mi­cro­bio­me drugs

Google Ven­tures-backed Evelo is join­ing forces with the Mayo Clin­ic to de­vel­op and even­tu­al­ly com­mer­cial­ize a fam­i­ly of gut bugs as med­i­cine.

You read that right. Evelo’s re­search is based on the idea that mi­crobes found in the gut can in­flu­ence bi­o­log­i­cal sys­tems through­out the rest of the body. If true, that means nat­u­ral­ly oc­cur­ring hu­man mi­crobes could po­ten­tial­ly be de­vel­oped as a new class of med­i­cine, the com­pa­ny’s CEO Sim­ba Gill tells me.

“What we have is a new modal­i­ty of med­i­cine that al­lows for oral, safe, con­ve­nient, and high­ly ef­fi­ca­cious drugs,” Gill said. “Sin­gle mi­crobes will act as med­i­cine to treat dis­ease.”

Mayo’s mi­crobes

Evelo calls these med­i­cine-wor­thy bugs “mon­o­clon­al mi­cro­bials,” and they’re not the on­ly ones in­trigued by their po­ten­tial phar­ma­co­log­i­cal us­es. The Mayo Clin­ic has been look­ing in­to this field for sev­er­al years, and re­cent­ly pub­lished da­ta in Cell and Arthri­tis and Rheuma­tol­ogy show­ing that pop­ping pills packed with cer­tain mi­cro­bials could sup­press mul­ti­ple scle­ro­sis and rheuma­toid arthri­tis. Mayo proved that in mice, and now Evelo wants to take the strain in­to the clin­ic.

The deal with Mayo gets Evelo a world­wide ex­clu­sive li­cense to the strains and sur­round­ing IP. The com­pa­ny did not dis­close the fi­nan­cial de­tails of the deal.

“This col­lab­o­ra­tion pro­vides us a new strain and fam­i­ly of mi­crobes backed by strong in­tel­lec­tu­al prop­er­ty,” Gill said. “Mayo has done great foun­da­tion­al work, and now we can rapid­ly take this fam­i­ly of mi­crobes in­to de­vel­op­ment by next year.”

Evelo isn’t di­vulging ex­act­ly which dis­eases it will take on first, but did say they’ll be look­ing in­to in­flam­ma­to­ry and neu­roin­flam­ma­to­ry dis­eases.

Evelo’s ex­ist­ing pipeline

As a com­pa­ny, Evelo emerged in 2016 by com­bin­ing two fledg­ling star­tups in­cu­bat­ed by Flag­ship Pi­o­neer­ing. Backed with $100 mil­lion from in­vestors in­clud­ing GV and Flag­ship, the com­pa­ny has been busy tak­ing on this am­bi­tious task of cre­at­ing a new drug modal­i­ty.

“What we’re do­ing is not straight for­ward,” Gill said. “Most peo­ple look at bal­anc­ing the gut ecosys­tem be­cause that’s the low hang­ing fruit. We went for the com­plex, more chal­leng­ing ap­proach. And that’s why we’re ahead of every­one else in this space.”

The new mi­crobes from Mayo add to Evelo’s ex­ist­ing vil­lage of mi­cro­bial fam­i­lies. The com­pa­ny is eval­u­at­ing how spe­cif­ic mi­crobes might in­flu­ence how the body’s im­mune sys­tem re­sponds to melanoma, re­nal and col­orec­tal can­cer, among oth­er dis­ease ar­eas. Gill was mum on ex­act­ly how many strains and pro­grams are on­go­ing, but said “sev­er­al” would en­ter the clin­ic next year.

The fu­ture of med­i­cine

Joseph Mur­ray

Gill has a rather bold pre­dic­tion that mon­o­clon­al mi­cro­bials will rev­o­lu­tion­ize med­i­cine.

“One of the rea­sons we’re so ex­cit­ed about this space is that — for many, many dif­fer­ent dis­eases — mon­o­clon­al mi­cro­bials could be used in com­bi­na­tion with or even dis­place bi­o­log­ics.”

And Mayo Clin­ic seems to agree.

“Our stud­ies show that hu­man de­rived mi­crobes can be used to treat mul­ti­ple im­muno­log­i­cal dis­eases well be­yond the gut,” said Joseph Mur­ray, pro­fes­sor of med­i­cine at Mayo Clin­ic.

Like the ad­vent of mon­o­clon­al an­ti­bod­ies, Gill be­lieves mon­o­clon­al mi­cro­bials will lead to a new wave of smarter drugs — more ef­fi­ca­cious, less tox­ic, and broad­ly ap­plic­a­ble to sev­er­al dis­ease ar­eas.

“Ef­fi­ca­cy, tox­i­c­i­ty, and con­ve­nience are the key at­trib­ut­es we’re look­ing at,” Gill said.

In those ar­eas so far, Gill said mon­o­clon­al mi­cro­bials’ per­for­mance is “strik­ing” in com­par­i­son to bi­o­log­ics.

BiTE® Plat­form and the Evo­lu­tion To­ward Off-The-Shelf Im­muno-On­col­o­gy Ap­proach­es

Despite rapid advances in the field of immuno-oncology that have transformed the cancer treatment landscape, many cancer patients are still left behind.1,2 Not every person has access to innovative therapies designed specifically to treat his or her disease. Many currently available immuno-oncology-based approaches and chemotherapies have brought long-term benefits to some patients — but many patients still need other therapeutic options.3

Gilead re­leas­es an­oth­er round of murky remde­sivir re­sults

A month after the NIH declared the first trial on remdesivir in Covid-19 a success, Gilead is out with new results on their antiviral. But although the study met one of its primary endpoints, the data are likely to only add to a growing debate over how effective the drug actually is.

In a Phase III trial, patients given a 5-day dose of remdesivir were 65% more likely to show “clinical improvement” compared to an arm given standard-of-care. The trial, though, gave little indication for whether the drug had an impact on key endpoints such as survival or time-to-recovery. And in a surprising twist, a 10-day dosing arm of remdesivir didn’t lead to a statistically significant improvement over standard of care.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,000+ biopharma pros reading Endpoints daily — and it's free.

Fangliang Zhang (Imaginechina via AP Images)

The big mon­ey: Poised to make drug R&D his­to­ry, a Chi­na biotech un­veils uni­corn rac­ing am­bi­tions in a bid to raise $350M-plus on Nas­daq

Almost exactly three years after Shanghai-based Legend came out of nowhere to steal the show at ASCO with jaw-dropping data on their BCMA-targeted CAR-T for multiple myeloma, the little player with Big Pharma connections is taking a giant step toward making it big on Wall Street. And this time they want to seal the deal on a global rep after staking out a unicorn valuation in what’s turned out to be a bull market for biotech IPOs — in the middle of a pandemic.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Len Schleifer (left) and George Yancopoulos, Regeneron (Vimeo)

Eyes on he­mo­phil­ia prize, Re­gen­eron adds a $100M wa­ger on joint de­vel­op­ment cam­paign with In­tel­lia

When George Yancopoulos first signed up Intellia to be its CRISPR/Cas9 partner on gene editing projects 4 years ago, the upstart smartly ramped up its IPO at the same time. Today, Regeneron $REGN is coming back in, adding $100 million in an upfront fee and equity to significantly boot up a whole roster of new development projects.

And they’re highlighting some clinical hemophilia research plans in the process.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,000+ biopharma pros reading Endpoints daily — and it's free.

Jean-Jacques Bienaimé, BioMarin chairman and CEO

Bio­Marin holds the line on bleeds with 4-year val­rox up­date on he­mo­phil­ia A — but what's this about an­oth­er de­cline in Fac­tor 8 lev­els?

BioMarin has posted some top-line results for their 4-year followup on the most advanced gene therapy for hemophilia A — extending its streak on keeping a handful of patients free of bleeds and off Factor VIII therapy, but likely stirring fresh worries over a continued drop in Factor VIII levels.

We just don’t know how big a drop.

We’ll see more data when the results are presented at the World Federation of Hemophilia in a couple of weeks. But in a statement out Sunday night, BioMarin $BMRN reported that none of the patients required Factor VIII treatment, adding:

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,000+ biopharma pros reading Endpoints daily — and it's free.

As­traZeneca trum­pets the 'mo­men­tous' da­ta they found for Tagris­so in an ad­ju­vant set­ting for NSCLC — but many of the ex­perts aren’t cheer­ing along

AstraZeneca is rolling out the big guns this evening to provide a salute to their ADAURA data on Tagrisso at ASCO.

Cancer R&D chief José Baselga calls the disease-free survival data for their drug in an adjuvant setting of early stage, epidermal growth factor receptor-mutated NSCLC patients following surgery “momentous.” Roy Herbst, the principal investigator out of Yale, calls it “transformative.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,000+ biopharma pros reading Endpoints daily — and it's free.

Pablo Legorreta, founder and CEO of Royalty Pharma AG, speaks at the annual Milken Institute Global Conference in Beverly Hills, California (Patrick T. Fallon/Bloomberg via Getty Images)

Cap­i­tal­iz­ing Pablo: The world’s biggest drug roy­al­ty buy­er is go­ing pub­lic. And the low-key CEO di­vulges a few se­crets along the way

Pablo Legorreta is one of the most influential players in biopharma you likely never heard of.

Over the last 24 years, Legorreta’s Royalty Pharma group has become, by its own reckoning, the biggest buyer of drug royalties in the world. The CEO and founder has bought up a stake in a lengthy list of the world’s biggest drug franchises, spending $18 billion in the process — $2.2 billion last year alone. And he’s become one of the best-paid execs in the industry, reaping $28 million from the cash flow last year while reserving 20% of the cash flow, less expenses, for himself.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,000+ biopharma pros reading Endpoints daily — and it's free.

Iterum's fu­ture looks un­cer­tain, af­ter lead an­tibi­ot­ic fails con­sec­u­tive piv­otal stud­ies

While the market for antibiotics remains in tatters — unlike many of its bankrupt (or at the brink of bankruptcy) peers — Iterum is suffering not because its antibiotic isn’t selling, but because the compound has now failed back-to-back late-stage studies.

The experimental drug, sulopenem, was designed to tackle drug-resistant infections with an outpatient focus (in addition to hospitals), to avert those reimbursement challenges that incentivize hospitals to prescribe cheaper, generic broad-spectrum antibiotics.

Covid-19 roundup: Did in­sid­ers cash in on pos­i­tive news re­port about Gilead be­fore pub­li­ca­tion?

A series of bullish trades on Gilead options just before the release of a favorable news story is raising questions among regulatory experts, Reuters reported.

On April 16, just hours before STAT published anecdotes from a Chicago hospital that served as one of the clinical sites to test Gilead’s remdesivir in Covid-19 patients, the California-based company’s shares were trading at around $75. Four large blocks of options were purchased for about $1.5 million each, betting that the stock would rise beyond that to as much as $87.5 by mid-August.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,000+ biopharma pros reading Endpoints daily — and it's free.